AAA January 2012 – Page 12

Priobiodrug compounds its funding with another $19m

Germany-based biopharmaceutical company Probiodrug secured €15m ($19.2m) in funding on Wednesday from investors including Biogen Idec New Ventures, a corporate venturing unit belonging to pharmaceutical corporation Biogen Idec, and biotechnology investment company BB Biotech. Also investing in the round were Edmond de Rothschild Investment Partners, which acts as a division of the Edmond de Rothschild… Continue reading Priobiodrug compounds its funding with another $19m

Abbott enters the world of NeuroGenetic

Abbott Biotech Ventures, one of the corporate venturing funds run by pharmaceutical corporation Abbott Laboratories, invested an undisclosed amount in US-based Alzheimer’s disease therapeutics company NeuroGenetic Pharmaceuticals (NGP) on Wednesday. Founded in 2009, NeuroGenetic’s technology is based around a compound, NGP555, that it claims can detect and reduce the brain plaques associated with Alzheimer’s. The… Continue reading Abbott enters the world of NeuroGenetic